Conclusion
Chirality and drugs
Article REF: P3340 V1
Conclusion
Chirality and drugs

Author : Serge KIRKIACHARIAN

Publication date: March 10, 2005, Review date: January 1, 2021 | Lire en français

Logo Techniques de l'Ingenieur You do not have access to this resource.
Request your free trial access! Free trial

Already subscribed?

7. Conclusion

The aim of this review is to highlight the importance of enantiomerism and geometric isomerism in the field of drugs.

Consequently, when an application is submitted for the marketing of an asymmetrical drug or a geometric isomer, the pharmaceutical dossier must include all physico-chemical studies guaranteeing the quality of the active ingredient, from manufacture and packaging through to the expiration date.

Given that two enantiomers or two geometric isomers can have different biological properties, it seems obvious that, before any new drug is launched on the market, the enantiomers or geometric isomers should be separated and their pharmacological, pharmacokinetic and toxicological properties studied. Such an approach would avoid the potential risks of toxicity, serious adverse effects and drug interactions resulting from the presence...

You do not have access to this resource.
Logo Techniques de l'Ingenieur

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed?


Article included in this offer

"Drugs and pharmaceuticals"

( 123 articles )

Complete knowledge base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

View offer details
Contact us